Sessions will focus on topics related to the foundation's shared missions and organizational best practices and processes to help do our jobs better. These topics should be particularly helpful for new staff members but hopefully will offer some useful “re-fresh” for experienced hands too.
Speaker Names:
Description: Several federal rules have been released the last few months that will have a very positive impact for people with disabilities including those with epilepsy. Come learn about the federal rulemaking process, how the Epilepsy Foundation and organizations like yours can engage and specifics about what the new rules do related to access to healthcare, air travel and web/mobile access.
Session Date: Thursday, June 20, 2024
Session Date: Thursday, April 4, 2024
Speakers Name: Caitlin Grzeskowiak, PhD, VP of Research and Innovation at EF
Description: Join us for an interactive session with Caitlin Grzeskowiak, PhD, where we discussed exciting innovations in epilepsy treatment and care. During the session, we explored the roadblocks and hurdles that new companies faced and examined the journey of an idea from the lab to commercialization.
Participants gained valuable insights into the challenges and opportunities within the field of epilepsy treatment and the intricate process of bringing new solutions to market.
Session Date: Thursday, February 15, 2024
Speakers Name: Wesley T. Kerr, MD, PhD, University of Pittsburgh
Description: Dr. Wesley Kerr is an epileptologist-statistician at the University of Pittsburgh. His clinical work focuses on the diagnosis and treatment of people with seizures that don’t respond to medications, including both medication-resistant epilepsy and functional (nonepileptic) seizures. His research focuses on using data to make better medical decisions and clinical trials. He was the primary developer of the Functional Seizures Likelihood Scale, which is a machine learning-based clinical support tool to promote early identification of functional seizures. This tool is the only tool of its kind that has both been prospectively validated and validated at an external center. His current work focuses on how data-driven insights can be integrated into clinical care, as well as the design of clinical trials.
Session Date: Thursday, February 1, 2024
Speakers Name: Alison Kukla, MPH, Senior Manager, Programs and Partnerships
Session Title: Partners Against Mortality in Epilepsy Meeting Summary
Description: Alison provided a detailed recap of the Partners Against Mortality and Epilepsy (PAME) conference, highlighting its significance, attendance statistics, and key speakers. The conversation covered the importance of discussing mortality and epilepsy prevention strategies, including discussions around mortality risks beyond SUDEP.
Session Date: Thursday, January 18, 2024
Speaker Name: Ilene Miller from REN and Caitlin Grzeskowiak from the EF Research & Innovation team
Description: This session will focus on The Rare Epilepsy Network (REN) Workshop held during the AES 2023 provided valuable insights into the organization's objectives and featured a comprehensive discussion during the REN breakfast. Attendees gained a deeper understanding of REN's mission and goals, contributing to a collective awareness of rare epilepsy issues.
Session Date: Thursday, November 2, 2023
Speaker Name: Cate Brocker, MSN, APRN, FNP-C, Senior Director, Programs & Partnerships Policy
Description: This session addressed the following key areas: the background and analysis of the network landscape, the rationale behind the Chronic Disease Self-Management Program (CDSMP), and an assessment of the current state of affairs concerning the CDSMP within the context of EF (Epidemic Foundation).
Date: Thursday, October 6, 2023
Speaker Name: Jacqueline French, MD, Chief Medical and Innovation Officer Editor and Research at the Epilepsy Foundation
Description: This session Dr. Jackie French shared invaluable insights on Epilepsy Treatments Update.
Date: Thursday, September 21, 2023
Speakers Name: Krista Schaaf, I&R Resource Specialist and Brandy Fureman, Chief Outcomes Officer, Mission Outcomes
Description: This session is on ways to improve medication adherence, which begins by screening clients for the barriers they may face in taking medications on time, as prescribed.
Session Date: Thursday, September 7, 2023
Speaker Name: Brandy Fureman, Chief Outcomes Officer, Mission Outcomes
Date: Thursday, June 15, 2023 - Speakers Name: Rahel Rosner, our Chief Financial and Operating Officer - Description: During the session, we explored exciting topic ideas that had been suggested by peers, including: Implementing new financial software, issuing an RFP and selecting new auditors, and managing expenses in an inflationary economy.
Date: Thursday, June 1, 2023 - Speakers Name: Laura Weidner, Vice President, Government Relations & Advocacy, Epilepsy Foundation of America
Date: May 18, 2023 Speakers Name: Jackie Acker, Director of Public Relations, at the Epilepsy Foundation of America Session Description or Objectives: Jackie will presented results showing the impact of the anti-stigma campaign, “Change our Epilepsy Story” in the pilot markets of Philadelphia and Phoenix.
Date: May 4, 2023 - Speakers Name: Sarah Klein, CEO, Epilepsy Foundation of Colorado & Wyoming - Session Description: Epilepsy and Mental Health Comorbidities: Supporting clients and raising awareness among behavioral health professionals.
Date: November 17, 2022
Date: March 2, 2023
Date: October 6, 2022
Date: September 1, 2022
Date: June 2, 2022
Date: March 17, 2022 - Learning Objectives: 1)Describe how drugs are selected for epilepsy management 2)Describe the goals of therapy 3)Review the list of recently approved anti-epilepsy medicines (AEDs)
Date: March 3, 2022 Learning Objectives: 1) Attendees will become familiar with the current understanding of stigma related to epilepsy 2) Attendees will be able to describe the purpose and main activities at EpiCON, and how they help address stigma
Date: February 17, 2022 - Learning Objectives: Describe two disparities in epilepsy that are related to social determinants of health
Date: January 20, 2022 - Learning Objectives: 1) Describe the evidence for 1/3 treatment-resistant claim 2) Improve critical thinking skills related to population-based estimates
